Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)

Blood (2023) 142 (Supplement 1): 104.

https://doi.org/10.1182/blood-2023-180242

Published: 2023

Journal Articles

Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2 ) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Frederick Lansigan, David Jacob Andorsky, Morton Coleman, Abdulraheem Yacoub, Jason Melear, Suzanne Fanning, Kathryn S. Kolibaba, Christopher M. Reynolds, Grzegorz S. Nowakowski, Mecide Gharibo, Jung Ryun Ahn, Ju Li, Mathias J. Rummel, Jeff P. Sharman

Blood (2021) 138 (Supplement 1): 812.

https://doi.org/10.1182/blood-2021-145640

Published: 2021

Journal Articles

Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance

Morton Coleman, MD FACP, David Jacob Andorsky, MD, Abdulraheem Yacoub, MD, Jason M. Melear, MD, Suzanne R. Fanning, DO, Kathryn S. Kolibaba, MD, Frederick Lansigan, MD, Christopher M. Reynolds, MD, Grzegorz S. Nowakowski, MD, Mecide Gharibo, MD, Erin Ahn, MS, Ju Li, PhD, Mathias J. Rummel, MD PhD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-134363

Published: 2020

Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Frederick Lansigan, MD, David Jacob Andorsky, MD, Morton Coleman, MD FACP, Abdulraheem Yacoub, MD, Jason M. Melear, MD, Suzanne R. Fanning, DO, Kathryn S. Kolibaba, MD, Christopher M. Reynolds, MD, Grzegorz S. Nowakowski, MD, Mecide Gharibo, MD, Erin Ahn, MS, Ju Li, PhD, Mathias J. Rummel, MD PhD, Jeff P Sharman, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-134193

Published: 2020

Journal Articles

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

Blood (2020) 135 (13): 996–1007.

https://doi.org/10.1182/blood.2019002395

Published: 2020

Includes: Supplemental data

Journal Articles

A Novel Gene Expression Classifier Enriches for Single Agent Clinical Activity of CC-122, a Cereblon Modulator, Administered Orally to Relapsed or Refractory Diffuse Large B-Cell Lymphoma Subjects: Results from the Phase I CC-122-ST-001 Study

Blood (2017) 130 (Supplement 1): 4118.

https://doi.org/10.1182/blood.V130.Suppl_1.4118.4118

Published: 2017

Journal Articles

CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma

Vincent Ribrag, MD, Silvia Damien, MD, Mecide Gharibo, MD, Mercede Gironella, MD, Armando Santoro, MD, Drew W Rasco, MD, William Edenfield, MD, Xin Wei, PhD, Angela James, PhD, Patrick Hagner, PhD, Anita K. Gandhi, PhD, Rajesh Chopra, MD PhD, Jorge F. DiMartino, MD PhD, Michael Pourdehnad, MD, Anne-Marie Stoppa, MD

Blood (2014) 124 (21): 3500.

https://doi.org/10.1182/blood.V124.21.3500.3500

Published: 2014

Journal Articles

A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Cavanagh Jamie, MD, Honorata Giongco Baylon, MD, Priscilla B. Caguioa, MD, Faith E. Davies, MD, Mecide Gharibo, MD, Shiro Akinaga, PhD, Michael R. Kurman, MD, Barbara A. Novak, BS, Kwee L. Yong, PhD

Blood (2013) 122 (21): 1967.

https://doi.org/10.1182/blood.V122.21.1967.1967

Published: 2013

Journal Articles

Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis

Asher Chanan-Khan, MD, Jeffrey L Wolf, MD, Juan Garcia, MD, Mecide Gharibo, MD, Sundar Jagannath, MD, Debbie Manfredi, Taimur Sher, MD, Cindi Martin, Sybil H Zildjian, MPH, James O'Leary, MD, Robert Vescio, MD

Blood (2010) 116 (21): 1962.

https://doi.org/10.1182/blood.V116.21.1962.1962

Published: 2010

Journal Articles

Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.

Asher Chanan-Khan, MD, Jeffrey Wolf, MD, Mecide Gharibo, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Debbie Manfredi, Kelvin P. Lee, MD, Kena C Miller, NP, Robin Guild, Sybil Zildjian, MPH, Albert Qin, MD, Ph.D., James O'Leary, MD, Robert Vescio, MD

Blood (2009) 114 (22): 2883.

https://doi.org/10.1182/blood.V114.22.2883.2883

Published: 2009

Journal Articles

Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma

Asher Alban Chanan-Khan, MD, Mecide Gharibo, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Kenneth C Anderson, MD, Dawn DePaolo, Kelvin P. Lee, MD, Kena Miller, RN, MSN, FNP, Robin Guild, Sybil Zildjian, Albert Qin

Blood (2008) 112 (11): 3689.

https://doi.org/10.1182/blood.V112.11.3689.3689

Published: 2008

NARROW

Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)

Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2 ) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in MAGNIFY: A Phase IIIb Interim Analysis of Induction R 2 Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier

A Novel Gene Expression Classifier Enriches for Single Agent Clinical Activity of CC-122, a Cereblon Modulator, Administered Orally to Relapsed or Refractory Diffuse Large B-Cell Lymphoma Subjects: Results from the Phase I CC-122-ST-001 Study

CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma

A Phase 1/2 Study Of KW-2478, An Hsp 90 Inhibitor, In Combination With Bortezomib (BTZ) In Patients (Pts) With Relapsed/Refractory (R/R) Multiple Myeloma (MM)

Efficacy Analysis From Phase I Study of Lorvotuzumab Mertansine (IMGN901), Used as Monotherapy, In Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Efficacy Analysis

Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.

Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only